Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5hmC Biomarker-Guided Therapy in Newly Diagnosed AML
NCT07060001Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, decitabine, venetoclax, cytarabine in acute myeloid leukemia (AML), sponsored by Houston Methodist Research Institute. Started Apr 2026; status: recruiting.
02
Drugs
azacitidinedecitabinevenetoclaxcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07060001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07060001.